Adeona Pharmaceuticals, based in Ann Arbor, MI., has received $1 million in equity financing from Florida-based investor Seaside 88, Adeona announced today. The financing involved the sale of 1,212,121 shares of stock. Adeona is working on a “prescription medical food” called Zinthionein ZC for treatment of Alzeimer’s disease and mild cognitive impairment. The company also announced that it has enrolled 75 percent of a 60-patient clinical study of Zinthionein ZC.
Author: Howard Lovy
Howard Lovy is a veteran journalist who has focused primarily on technology, science and innovation during the past decade.
In 2001, he helped launch Small Times Magazine, a nanotech publication based in Ann Arbor, MI, where he built the freelance team and worked closely with writers to set the tone and style for an emerging sector that had never before been covered from a business perspective. Lovy's work at Small Times, and on one of the first nanotechnology-themed blogs, helped him earn a reputation for making complex subjects understandable, interesting, and even entertaining for a broad audience. It also earned him the 2004 Prize in Communication from the Foresight Institute, a nanotech think tank.
In his freelance work, Lovy covers nanotechnology in addition to technological innovation in Michigan with an emphasis on efforts to survive and retool in the state's post-automotive age. Lovy's work has appeared in many publications, including Wired News, Salon.com, the Wall Street Journal, The Detroit News, The Scientist, the Forbes/Wolfe Nanotech Report, Michigan Messenger, and the Ann Arbor Chronicle.
View all posts by Howard Lovy